10x Genomics shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral and lowered its price target from $40 to $20.
Portfolio Pulse from Benzinga Newsdesk
10x Genomics shares are trading lower after JP Morgan downgraded the stock from Overweight to Neutral and lowered its price target from $40 to $20.
July 18, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
10x Genomics shares are trading lower following a downgrade by JP Morgan from Overweight to Neutral, with a reduced price target from $40 to $20.
The downgrade by a major financial institution like JP Morgan, along with a significant reduction in the price target, is likely to negatively impact investor sentiment and lead to a short-term decline in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100